Objective: Serious mental illness and type II diabetes mellitus have a high comorbidity, and both have a higher prevalence of anxiety disorders compared to the general population. Targeted Training in Illness Management is a group-based self-management training approach which targets serious mental illness and type II diabetes mellitus concurrently. This analysis examines data from a randomized controlled trial of Targeted Training in Illness Management intervention to examine the impact of comorbid anxiety on baseline psychiatric symptomatology and diabetic control, and on longitudinal treatment outcomes. Methods: We conducted secondary analyses on data from a prospective, 60-week, randomized controlled trial testing Targeted Training in Illness Management versus treatment as usual in 200 individuals with serious mental illness and diabetes. Primary outcomes included measures related to serious mental illness symptoms, functional status, general health status, and diabetes control. Measures were compared between those participants with anxiety disorders versus those without anxiety at baseline as well as over time using linear mixed effects analyses. Results: Forty seven percent of the participants had one or more anxiety disorders. At baseline, those with an anxiety diagnosis had higher illness severity, depressive, and other psychiatric symptomatology and disability. Diabetic control (HbA1c) was not significantly different at baseline. In the longitudinal analyses, no significant mean slope differences over time (group-by-time interaction effect)
Introduction
It is known that patients with serious mental illness (SMI) have a higher prevalence of anxiety disorders when compared to the general population. [1] [2] [3] In one systematic review, 40 .2% of patients with schizophrenia or schizoaffective disorder, 51.5% of bipolar disorder patients, and 55.6% of patients with depressive disorder expressed feeling frequent or constant anxiety. 4 Evidence supports that patients with SMI and comorbid anxiety disorder not only have elevated depressive and psychotic symptoms compared to those without anxiety but also lower social functioning 5 and quality of life. 6 The problem is compounded by the fact that these patients tend to have their anxiety disorders inadequately addressed or treated. 7 Type II diabetes mellitus (DM2) is another positively correlated comorbidity for patients with SMI. With age/sex-matched controls, patients with SMI have a higher prevalence of DM2 and greater overall illness burden. [8] [9] [10] [11] [12] [13] [14] This includes not only poor glycemic control but also worsening of disability, increased general complications, higher rate of mortality, and decreased quality of life. 15, 16 Studies have shown that second-generation antipsychotics increase the chances of developing DM2, [17] [18] [19] [20] beyond the increased physiologic risk prior to the administration of pharmaceuticals. 21 Patients with both conditions often perceive barriers keeping them from proper disease management in the form of increased stress and isolation, lack of support from family and friends, and poor communication/integration with their healthcare team. 22 People with DM2 have an increased risk of experiencing anxiety disorders and elevated anxiety symptoms. 23 In one systematic review, generalized anxiety disorder (GAD) was present in 14% and elevated symptoms of anxiety were present in 40% of patients with diabetes mellitus. 24 Numerous studies show that the presence of comorbid anxiety with diabetes mellitus is associated with poor glycemic control. 25 Diabetics with elevated anxiety and/or depression symptoms are less likely to report adhering to self-care recommendations. 26 Lifetime depression and anxiety with DM2 increased the risk of more severe psychological symptoms, hyperglycemia, and difficulties with healthy behavior. 27 One study suggests that when treating a patient with both DM2 and SMI, using cognitive remediation strategies and functional adaptation skills training, can lead to better outcomes. 28 Targeted Training in Illness Management (TTIM) is a group-based self-management training approach which targets SMI and DM2 concurrently. TTIM uses psychoeducation, goal setting, behavioral modeling, and care linkage applying the principles of social cognitive theory. 29 Added on to a normal treatment regimen, the TTIM approach has been shown to improve outcomes in randomized controlled trial (RCT) conditions in a population with SMI and comorbid diabetes. 30 Using interim baseline data from the TTIM study, we have previously reported relationships among comorbid anxiety, glucose control as measured by HbA1c level, and overall illness burden. 31 In a preliminary, cross-sectional sample of 157 patients, anxiety disorders were seen in 33.1% of participants with SMI and DM2 and were associated with increased severity of depressive symptoms and decreased function. At baseline, HbA1c levels were not significantly different in those with or without anxiety, and having multiple anxiety disorders was not associated with differences in DM2 control. 31 This manuscript reports the updated analysis of baseline data from the complete sample of 200 study participants in the TTIM study and compares longitudinal data on primary outcomes between participants with anxiety disorders versus those without anxiety. Findings can help inform care approaches for individuals with SMI and complex comorbidity.
Methods
TTIM is derived from the Life Goals Program, by Bauer et al. and the Diabetes Awareness and Rehabilitation Training by McKibbin et al. [32] [33] [34] The delivery of TTIM in a two-step process has been described in detail in an earlier publication. 29, 35 In step 1, 12 weekly, group-format, in-person sessions (6-10 participants per group) are codelivered by a nurse educator and a peer educator with SMI and DM2. In step 2, over the 48 weeks following the group sessions, participants have brief (10-15 min) telephone maintenance sessions with peer educators and nurse educators. Telephone sessions occur every other week for the first three months and monthly thereafter.
This project was a NIMH-funded prospective, 60-week, RCT testing TTIM versus treatment as usual (TAU) in 200 individuals with SMI and diabetes conducted in a safety-net health system primary care setting. Research assessments were conducted at baseline (prior to randomization) and at 13, 30, and 60 weeks. A detailed report on recruitment and retention methods for this study has been previously published. 36 Individuals were referred for participation in the study by their clinicians and individuals also self-referred in response to IRB-approved study advertisements. In addition to clinician referrals and selfreferrals, eligible participants were sought via an IRB-approved protocol that identified individuals with SMI-DM in the medical records of a tertiary care teaching hospital. Individuals were identified from the health system's electronic health record, either by having SMI on their problem list or being treated with medication for SMI (lithium, mood stabilizer, antipsychotic). Using an IRBapproved process, these individuals were consecutively contacted and invited to participate in the study. All study participants had DM2 and schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive disorder confirmed by the Mini-International Neuropsychiatric Interview. 37 The RCT had multiple primary outcomes evaluating four domains: mental illness symptom severity, functioning, general health, and DM control. Additional physical health outcomes included body mass index (BMI) and blood pressure.
Primary outcomes of mental illness symptom severity were Brief Psychiatric Rating Scale (BPRS), Montgomery-Asberg Depression Scale (MADRS), and Clinical Global Impression (CGI). The BPRS 38 measures psychotic and nonpsychotic symptoms in SMI. Possible scores range from 7 to 126, with higher scores indicating greater symptom severity. The MADRS is a 10-item depression severity scale widely utilized in studies with patients with SMI. 39 Possible scores range from 0 to 60 with higher scores indicating worse depression. The CGI is a broad measure of global psychopathology that evaluates illness severity on a 1-7 point continuum. 40 Possible scores range from 0 to 7, with higher scores indicating greater psychopathology.
Functional status was evaluated using Global Assessment of Functioning (GAF) and Sheehan Disability Scale (SDS). The GAF is a 100-point singleitem scale that measures global functioning. 41 Possible scores range from 1 to 100, with higher scores indicating better functioning. The SDS measures role impairment in three domains (work/school, family life/home, social life). 42 Possible scores range from 0 to 30, with higher scores indicating greater disability.
General Health Status outcome was the Short Form 36 Health Survey (SF-36), which is a self-report of general health 43 divided into a physical component summary and mental component summary. Norm-based scores are placed on the same metric with a mean of 50 and standard deviation of 10. Scores above 50 reflect higher functional status than the average population and scores below 50 reflect lower than average function.
DM control was evaluated with serum glycosylated hemoglobin (HbA1c) drawn at study baseline, 30 weeks, and 60 weeks. This indicates relative DM control over the past three months with scores ideally < 7.
Data analysis
Data analyses were conducted in SAS software version 9.3, SPSS version 23, and R software version for 64-bit Windows operating system. The level of significance except where noted otherwise was a ¼ .05.
For purposes of this study, all DSM-IV anxiety disorder diagnoses were included except for Obsessive-Compulsive Disorder (OCD), based on agreement by study investigators that OCD patients were not representative of the anxiety cohort as a whole.
For baseline analysis, we report descriptive statistics, including means and standard deviation within SMI diagnosis groups, in a pooled sample of those in TAU or TTIM. We also report the p-value from the nonparametric Kruskal-Wallis one-way analysis of variance by ranks across diagnostic groups. In our longitudinal analyses for the primary outcomes, we evaluate potential differences in the group-by-time interaction effect using linear mixed effects analyses. These series of mixed effects models (separate for each outcome) also included main effects for group and time along with a random intercept. A mixed effects approach is particularly suited for dealing with missing data by a maximum likelihood algorithm under the assumption that the missingness is dependent on the data at hand.
Results

Sample description
In this analysis all subjects were pooled, regardless of treatment assignment. Almost half of the participants, 94 out of 200 (47.0%), had one or more anxiety disorder, indicating a high prevalence of comorbid anxiety in this group of patients with SMI and DM2. Table 1 contains the proportion of participants with particular anxiety disorders. Prevalence of these anxiety disorders in reported US samples with schizophrenia, DM2, and the general US population has been provided for relative comparison. GAD was the most common anxiety disorder in this study population.
Baseline demographic and clinical differences
In this analysis all subjects were pooled, regardless of treatment assignment. No significant demographic differences with regards to age, gender, race, and education were detected in those with and without anxiety disorders. No significant differences were found for SMI diagnosis (p ¼ 0.2006), SMI duration For SMI symptoms and severity, significant differences were found in CGI, MADRS, and BPRS scores. Those with anxiety diagnosis had higher CGI scores (p ¼ 0.0006), higher MADRS scores (p ¼ 0.0003), and higher BPRS scores (p ¼ 0.0055), indicating higher illness severity, depressive symptoms, and overall psychiatric symptomatology, respectively. SDS scores were significantly higher in anxiety participants (p ¼ 0.0002), indicating higher disability at baseline. Anxiety participants also had significantly lower SF-36 mental scores (p < 0.0001), reflective of lower relative functional health status. Participants with comorbid anxiety had lower mean GAF score, but this does not reach statistical significance (p ¼ 0.1468). These results are summarized in Table 2 .
No significant differences were found between the two groups in baseline HbA1c (p ¼
Differences in longitudinal outcomes
We evaluated on our primary outcomes whether there were significant slope differences over time (group-by-time interaction effect) within the treatment groups between those with and without anxiety disorders.
No significant differences were found between those with anxiety diagnoses and those without in the TAU group for any of the primary outcome measures studied (all p values >0.05) (see Table 3 ).
Within the TTIM subgroup there were significant group-by-time interaction effects over the 60 weeks between those with and without anxiety disorders for GAF, SF 36 Mental, and HbA1C (p-values 0.037, 0.020, and 0.030, respectively). Also, trends were seen for the MADRAS and BPRS (p-values 0.075 and 0.079, respectively) (see Table 3 ). No significant group-by-time interaction effects were found for CGI, SF36 General Health, and SDS.
At all points of measurement from baseline to 60 weeks, those with anxiety comorbidity had lower GAF values, reflecting relatively poor functioning; however, the improvement in GAF in the anxiety comorbidity group with TTIM intervention was greater (10.6 points) than the improvement in GAF in participants without anxiety disorders (8.2 points). Those with anxiety comorbidity had lower SF-36 Mental scores at all points of measurement from baseline to 60 weeks and also experienced a smaller increase in score (4.7 points) compared to those without anxiety (5.3 points).
Those with anxiety had higher MADRS and BPRS scores at all points compared to those without anxiety, however, experienced a greater improvement in 
BPRS (8.2 points versus 5.3 points).
While not statistically significant in terms of the group-by-time interaction effect, the trend was still noted. Those with anxiety comorbidity in the TTIM group had lower HbA1c values and less dispersion at baseline, 30 weeks, and 60 weeks compared to those with no anxiety, indicative of better diabetic control. The change in HbA1c at 60 weeks from baseline was the same for those with and without anxiety disorders (0.2%). From baseline to 30 weeks, however, those with anxiety disorders experienced a decrease in mean HbA1c value while mean HbA1c value was unchanged in those without anxiety disorders. The difference in HbA1c between the two curves is greatest at 30 weeks ( Figure 1) . No significant slope differences over time between those with and without anxiety disorders in systolic BP and BMI were found (p-values 0.813 and 0.760, respectively).
Discussion
Findings from the pooled TTIM study samples show that anxiety disorders in individuals with SMI and DM2 are very common. While in our earlier preliminary baseline analysis, approximately one-third of participants in the sample had a comorbid anxiety disorder; the results of the final analysis show an even greater burden with approximately half of the participants carrying one or more anxiety disorder diagnosis. While elevated prevalence rates of anxiety in the SMI population or DM2 population have been reported separately, 2, 3, 23 the findings from the TTIM study are novel in that they report findings from individuals with both SMI and DM2. At baseline, comorbid anxiety was related to increased psychiatric symptomatology, particularly depression, and worse functioning and disability in the pooled samples. This is consistent with our previous preliminary analysis, as well as existing literature which shows that anxiety can exacerbate core symptoms of other psychiatric disorders related to worse prognosis. 5, 6 While a statistically significant difference in GAF was not found at baseline, longitudinal data on the primary outcomes suggested those with anxiety in the TTIM group had lower GAF and SF-36 scores (p-values 0.037 and 0.020, respectively) over time compared to those without comorbid anxiety diagnoses, and trends were seen for higher MADRS and BPRS scores over time. A differential effect of the TTIM intervention needs to be pointed out. While both groups (with and without anxiety comorbidity) experienced improved psychiatric symptomatology with the TTIM intervention, the anxiety comorbidity group experienced a greater magnitude of improvement from baseline compared to no anxiety group in GAF (statistically significant p ¼ 0.037) and BPRS (not statistically significant but a trend p ¼ 0.079). The TTIM intervention is effective for participants both with and without anxiety comorbidity, but the magnitude of improvement may be larger in those with anxiety comorbidity.
As measured by HbA1c, we did not find evidence that comorbid anxiety is associated with worse diabetic control at baseline (p ¼ 0.2817). It is possible that anxiety makes participants with SMI and DM2 more aware about the potential risks of poorly controlled diabetes, accompanied by more consciousness of the need to control diet and weight. A negative association between anxiety and diabetic control in DM2 participants alone has been reported previously but inconsistently. [45] [46] [47] [48] [49] In the longitudinal analyses, participants in the TTIM group with comorbid anxiety showed significantly lower HbA1c levels (p ¼ 0.030) and lower spread 50 over time compared to those without anxiety. This is in the opposite direction of what we had expected. An inverted-U-shape relationship between levels of anxiety and functioning has been previously reported, 51 and it may be the case that in our sample, anxiety symptoms could potentially have helped to promote awareness and healthy behaviors relevant to diabetic control. For the first 30 weeks of the study, those with comorbid anxiety experienced a greater decline in HbA1c values (by 0.4%) compared to those without (0.0%), but the overall change in HbA1c values between the two at 60 weeks was the same as it was at baseline. This may suggest that those with comorbid anxiety respond better to the TTIM intervention in the weeks after the intervention, but the differential effect is not sustained over time. Given that this is a post hoc secondary analysis, more study would be required to better understand the relationship between anxiety, TTIM, and diabetes control.
Several limitations to our study need to be pointed out. It was conducted at a single site; we did not have complete information about mental health treatments; psychotropic medications were not a specific focus of the intervention; and there are questions about generalizability of our sample to a general clinical population. Other confounding factors, such as cognitive deficits, psychotic symptoms, and medication adverse effects, can independently influence diabetic control and adherence to treatment. Strengths of the study include the rigorous randomized control design and well-characterized population with both SMI and DM2 diabetes.
Conclusion
Individuals with SMI and DM2 experience a very high prevalence of anxiety disorders. Comorbid anxiety disorders in this population are associated with worse psychiatric symptoms, lower functioning, and greater disability. The TTIM intervention appears to lead to greater improvement in functioning from baseline in those with comorbid anxiety disorders. Anxiety comorbidity in the SMI and DM2 population does not appear to have a negative impact on diabetic control. There is a need for further study to better characterize these complex relationships.
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